Speaker: Andrew Kuykendall

0:01:31

Young patients with myelofibrosis commonly exhibit inflammatory comorbidities

0:02:16

The current state-of-the-art in MF and PV therapy and future outlooks

0:01:39

The need for disease-modifying therapies in MPNs

0:06:37

Drivers of progression in MPNs and the importance of early intervention

1:30:32

Integrating New Research Information into Current Clinical Care — Myelofibrosis

0:01:40

Challenges and options for patients with hydroxyurea-resistant PV

0:01:14

Insights into novel agents and potential combination therapies being explored in MF

0:04:09

Risk factors for progression in MPNs

0:01:49

Phase II trial-in-progress of itacitinib in patients with myelofibrosis

0:02:03

Preliminary results of a Phase II study of fedratinib in patients with MDS/MPN and CNL

0:01:41

The future of MPN therapy

0:03:51

Genetic mechanisms driving thrombocytopenia in MF patients

0:01:28

Momelotinib in 2024: how should this agent be used in MF with anemia?

0:01:55

The promise of pelabresib in MF and insights into the MANIFEST-2 study

0:02:40

Patient risk stratification in MPNs: current and future approaches

0:01:12

Contemporary challenges in polycythemia vera management

0:01:13

The challenges of treating patients with MPNs who possess a TP53 mutation

0:02:45

An insight into clinical risk factors for progression in MPNs

0:02:04

Novel therapies for myelofibrosis patients who have failed JAK inhibitors

0:03:21

Retrospective analysis of lenalidomide and thalidomide in myelofibrosis

0:02:06

Thromboembolic event rates in patients with PV: a real-world analysis

0:02:09

Serum albumin as a dynamic treatment-specific surrogate for outcomes in rux-treated pts with MF

0:01:11

Highlights from the 2022 Texas MPN Workshop

0:01:01

Latest advances in myelofibrosis treatment